Immunitybio, Inc. (IBRX) fundamentals score
• its ability to develop next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases;
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 4.8 out of 10, Weak long-term fundamentals
- Growth: 4.3/10
- Profitability: 5.0/10
- Financial health: 5.8/10
- Earnings quality: 4.0/10
- Valuation: 4.6/10
Scores are calculated from Immunitybio, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10